Industry News

Agreement Signed for Potential Hepatitis B, HIV Treatment

Published in AIDS Weekly, April 10th, 2000

Vion Pharmaceuticals, Inc. (Vion) and Achillion Pharmaceuticals, Inc., announced that they have signed a licensing agreement for Vion's novel antiviral technology, nucleoside analog (beta)-L-Fd4C, for the potential treatment of hepatitis B virus and HIV.

Achillion, a privately held biopharmaceutical company located in New Haven, recently completed a Series B financing and is commencing operations to develop and commercialize innovative antiviral therapies. Under the terms of the license agreement, Achillion will fund the development of (beta)-L-Fd4C, which it intends to develop as one of its key product candidates.

Preclinical studies of...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of AIDS Weekly

Source: AIDS Weekly (2000-04-10)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry